NCT02350764View on ClinicalTrials.gov

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

PHASE2CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

September 25, 2023

Study Completion Date

September 25, 2023

Conditions

Advanced Stage Non-small Cell Lung Cancer

Interventions

DRUG

nivolumab

DRUG

pilimumab

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER